More than 25% of U.S. adults with diabetes used GLP-1 drugs like Mounjaro and Ozempic in 2024, according to a CDC survey. These injectable medications, targeting the GLP-1 protein, are also marketed for weight loss under different names. The drugs are often used in combination with insulin or oral diabetes medications, reflecting their integration into treatment regimens.
Full Story: Reuters (8/13)